Proparacaine

Generic Name
Proparacaine
Brand Names
Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
Drug Type
Small Molecule
Chemical Formula
C16H26N2O3
CAS Number
499-67-2
Unique Ingredient Identifier
B4OB0JHI1X
Background

Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.

Indication

Used as a local (ophthalmic) anesthetic.

Associated Conditions
Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Associated Therapies
Local Anaesthesia therapy
Clinical Trials
Related News

A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS)

Phase 2
Completed
Conditions
Complex Regional Pain Syndrome (RSD)
Interventions
Drug: Lenalidomide
First Posted Date
2003-08-27
Last Posted Date
2008-01-03
Lead Sponsor
Celgene Corporation
Target Recruit Count
40
Registration Number
NCT00067743
Locations
🇺🇸

Swedish Pain Management, Seattle, Washington, United States

🇺🇸

UNC Hospitals University of North Carolina, Chapel Hill, North Carolina, United States

🇺🇸

Drexel University College of Medicine, Philadelphia, Pennsylvania, United States

and more 3 locations

Lenalidomide Safety/Efficacy in Myelodysplastic Syndromes (MDS) Associated With a Deletion (Del)(5q) Cytogenetic Abnormality

Phase 2
Completed
Conditions
Myelodysplastic Syndromes
Interventions
Drug: lenalidomide
First Posted Date
2003-07-18
Last Posted Date
2019-11-19
Lead Sponsor
Celgene
Target Recruit Count
148
Registration Number
NCT00065156
Locations
🇺🇸

Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

Desert Hematology & Oncology Medical Group, Rancho Mirage, California, United States

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

and more 26 locations

S0232 Dexamethasone With or Without Lenalidomide in Treating Patients With Previously Untreated Stage I, Stage II, or Stage III Multiple Myeloma

First Posted Date
2003-07-09
Last Posted Date
2015-03-25
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
198
Registration Number
NCT00064038
Locations
🇺🇸

William Beaumont Hospital - Royal Oak Campus, Royal Oak, Michigan, United States

🇺🇸

Utah Cancer Specialists at UCS Cancer Center, Salt Lake City, Utah, United States

CC-5013 in Treating Patients With Cancer That Has Not Responded to Previous Therapy

First Posted Date
2003-01-27
Last Posted Date
2012-03-15
Lead Sponsor
National Institutes of Health Clinical Center (CC)
Registration Number
NCT00031941
Locations
🇺🇸

NCI - Center for Cancer Research, Bethesda, Maryland, United States

🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

CC-5013 in Treating Patients With Recurrent Glioma

Phase 1
Completed
Conditions
Brain and Central Nervous System Tumors
First Posted Date
2003-01-27
Last Posted Date
2015-04-30
Lead Sponsor
National Cancer Institute (NCI)
Registration Number
NCT00036894
Locations
🇺🇸

Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States

Phase 1 Study OF CDC-501 in Patients With Solid Tumors

Phase 1
Completed
Conditions
Neoplasms
Interventions
Drug: Lenalidomide
First Posted Date
2002-10-03
Last Posted Date
2019-11-18
Lead Sponsor
Celgene
Target Recruit Count
24
Registration Number
NCT00046735
Locations
🇺🇸

Wake Forest University, Winston-Salem, North Carolina, United States

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy